Dr. Stephen Nicholls and Dr. C. Michael Gibson Discuss: A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles (KRAKEN) November 18, 2024 2024 | AHA | Cardiology | Trial | Video Disclosures: TBD AHA KRAKEN nov14Download Article Navigation Dr. Steven E Nissen and Dr. C. Michael Gibson Discuss: ALPACAR Phase 2 Trial of Zerlasiran: Multiple Doses of a Short-Interfering RNA Targeting Lipoprotein(a) Over 60 weeks. Dr. Katherine R Tuttle and Dr. C. Michael Gibson Discuss: Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial
